The Global Colorectal Cancer Diagnostics Market Anticipated to Achieve 8.5% CAGR during the Forecast Period 2017 To 2022, Finds Fact.MR

In order to study the various trends and patterns prevailing in the concerned market, FactMR has included a new report titled “The Global Colorectal Cancer Diagnostics Market Anticipated to Achieve 8.5% CAGR during the Forecast Period 2017 To 2022, Finds FactMR” to its wide online database including upcoming trends and growth factors. This research assessment offers a clear insight about the influential factors that are expected to transform the global market in the near future. The report studies the colorectal cancer diagnostics market worldwide, especially in North America, Europe, Southeast Asia, India and Other Regions with production, size, growth, revenue, consumption, import and export in these regions. The intelligent report also anticipates that the market would grow at a constructive CAGR until 2022.

Request for a Free Sample Report - https://www.factmr.com/connectus/sample?flag=S&rep_id=70

Colorectal cancer diagnostics are a wide range of screening tests and diagnosis procedures that are employed before treating a patient with colon cancer. A typical diagnosis of colorectal cancer consists of tests such as colonoscopy, biopsy, blood sample testing, CT scan, ultrasound, MRI and molecular testing of the growing tumor. A recent report by FactMR projects the global colorectal cancer diagnostics market to register an impressive expansion at 8.5% CAGR during the forecast period 2017 to 2022. Revenues from the global colorectal cancer diagnostics market is expected to surpass US$ 2,000 Mn by 2022-end.

The emergence of new improved diagnosis tests, soaring uptakes of diagnosis-associated therapies, and increasing initiatives by private and government organisations are factors likely to fuel growth of the global colorectal cancer diagnostics market. Surging unmet requirements for colorectal cancer diagnostics around many emerging economies, along with the shortage of neoadjuvant as well as adjuvant pipeline agents for diagnosing high-risk patients suffering from resectable colorectal cancer is anticipated to pave tremendous growth opportunities for global leaders in the market. In contrast, factors such as rising patient reluctance against medications of colorectal cancer, and absence of awareness about therapeutics and diagnostics of colorectal cancer in many remote regions around the world is estimated to impede the market growth.

The World Cancer Research Fund estimates the colorectal cancer to be the third-most occurring form of cancer around the world. In 2012, more than 1 Mn people were diagnosed with colorectal cancer. Majority of these were reported in the developed economies, and this is anticipated to surge in the near future. These incidences of colorectal cancer have boosted demand for their diagnostics worldwide.

Browse Colorectal Cancer Diagnostics Market Report with TOC – https://www.factmr.com/report/70/colorectal-cancer-diagnostics-market

In addition, the number of deaths caused by colorectal cancer has witnessed a decline over the recent past, on the back of awareness spread by American Cancer Society (ACS). Introduction of effective instruments, along with the development of screening methods are estimated to further propel growth of the global market for colorectal cancer diagnostics. The market for colorectal cancer diagnostics in Asia Pacific excluding Japan (APEJ) is estimated to exhibit the fastest expansion throughout the forecast period. Revenue from the market in Middle East & Africa (MEA) will continue to be sluggish during the forecast period. North America will remain the most lucrative region for colorectal cancer diagnostics. North America’s colorectal cancer diagnostics market is anticipated to account for nearly US$ 800 Mn in revenues by 2022-end. Markets in Europe and North America are estimated to register a parallel expansion at a CAGR of 8.6% through 2022.

FOB tests will remain the largest adopted tests for colorectal cancer diagnostics across the globe. In addition, FOB tests in the global colorectal cancer diagnostics market will account for the largest revenues, followed by CTC tests. The immunochemistry tests will register the highest CAGR in the market through 2022. However, BRAF tests will account for the lowest revenues in the global market for colorectal cancer diagnostics throughout the forecast period.

Based on end-users, even though hospital-associated labs are estimated to remain sought-after for colorectal cancer diagnostics, cancer research institutes will register the fastest expansion through 2022. Hospital-associated labs in the global colorectal cancer diagnostics market are estimated to account for nearly US$ 1,000 Mn in revenues by 2022-end. In addition, independent diagnostic laboratories will remain the second largest end-users of colorectal cancer diagnostics in the global market.

Competition Tracking

The report has also profiled prominent players in the global market for colorectal cancer diagnostics, which include Illumina, Inc, Sysmex Corporation, Danaher Corporation, Rosetta Genomics, Epigenomics AG, Exact Science Corporation, Pathway Genomics Corporation, Biocept, Inc., Cancer Genetics, Inc, and Foundation Medicine, Inc.

Do You Have Any Query or Specific Requirement? Ask Our Industry Expert - https://www.factmr.com/connectus/sample?flag=AE&rep_id=70

About FactMR

FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

FactMR
11140 Rockville Pike
Suite 400, Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/

This release was published on openPR.